PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - Registrational Phase 3 in PH-ILD Expected to Commence in Second Half of 2025 - Seralutinib Receives Orphan Drug Designation for PAH in Japan - Cash, cash equivalents and marketable securities totaled $295 million at year-end 2024 - SAN DIEGO / Mar 13, 2025 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical... Read More

SAN DIEGO / Mar 07, 2025 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the... Read More

SAN DIEGO / Feb 07, 2025 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant,... Read More

SAN DIEGO / Feb 03, 2025 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented one oral presentation and three posters related to seralutinib at the Pulmonary Vascular... Read More

Gossamer to Present Preclinical Evidence of Synergistic Treatment Effect from Combination Seralutinib & Sotatercept in Models of PAH SAN DIEGO / Jan 28, 2025 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with... Read More

SAN DIEGO / Nov 11, 2024 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant,... Read More

$327 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2024 SAN DIEGO / Nov 07, 2024 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced... Read More

SAN DIEGO / Oct 07, 2024 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant,... Read More

Additional Phase 2 TORREY Open-Label Extension Data to be Presented in Vienna SAN DIEGO / Aug 26, 2024 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced two oral... Read More

$354 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2024 SAN DIEGO / Aug 12, 2024 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its... Read More

SAN DIEGO / Jun 07, 2024 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant,... Read More

SAN DIEGO / May 14, 2024 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024... Read More

SAN DIEGO / May 10, 2024 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant,... Read More

Transformative Development and Co-Commercialization Collaboration with Chiesi Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 TORREY Phase 2 PAH Results Published in Lancet Respiratory Medicine Latest PAH Open-Label Extension Dataset to be Presented at ATS in San Diego on May 19th $396 Million in Cash, Cash Equivalents & Marketable... Read More

Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory and $180 million in sales milestones - Gossamer leading US commercialization activities in PAH and PH-ILD 50 / 50 commercial profit split in US and global development cost sharing arrangement Chiesi, a global leader in the pulmonary and rare disease spaces, obtains exclusive ex-US commercial rights,... Read More

SAN DIEGO / May 03, 2024 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the publication of its TORREY Phase 2 study manuscript in the Lancet Respiratory Medicine... Read More

SAN DIEGO / Mar 12, 2024 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors. Dr.... Read More

First PAH Patient Dosed in Ongoing Registrational Phase 3 PROSERA Study Inclusion of Japan in Phase 3 PROSERA Study Following CTN Acceptance by PMDA Cash, cash equivalents and marketable securities totaled $296 million at year-end 2023 SAN DIEGO / Mar 05, 2024 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the... Read More

SAN DIEGO / Jan 08, 2024 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 5, 2024, to two new non-executive employees of non-qualified... Read More

SAN DIEGO / Dec 13, 2023 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical... Read More

SAN DIEGO / Dec 05, 2023 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it has granted stock options to Bob Smith, Gossamer’s newly appointed Chief Commercial Officer. The Compensation Committee of Gossamer’s Board of Directors... Read More

Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck Previously, Mr. Smith led US sales operations for Actelion SAN DIEGO / Dec 05, 2023 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial... Read More

SAN DIEGO / Nov 29, 2023 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors. “Today, we are thrilled to announce that Dr. John Quisel... Read More

Phase 3 PROSERA Site Activations Proceeding Ahead of Schedule; First Dosing Expected in 4Q23 Additional Data from TORREY Open-Label Extension Expected in 4Q23 $329 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2023 SAN DIEGO / Nov 09, 2023 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of... Read More

SAN DIEGO / Oct 03, 2023 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs. Dr. Zimmermann brings more than 23 years of experience within the PAH/PH... Read More

SAN DIEGO / Sep 07, 2023 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that data from its functional respiratory imaging, or FRI, sub-study of the successful Phase 2 TORREY Study of seralutinib in patients with PAH will be presented at... Read More

Seralutinib Phase 3 PROSERA Study in PAH Patients Expected to Initiate in 3Q23 Additional Data from TORREY Open-Label Extension Expected in 4Q23 or 1Q24 $374 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2023, Pro Forma for Gross Proceeds of $212 Million from a Private Placement Financing in July 2023 SAN DIEGO / Aug 08, 2023 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage... Read More

Call will be held on Tuesday, July 25 th beginning at 10 a.m. EDT SAN DIEGO / Jul 24, 2023 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced today that it will hold a conference call with PAH experts on Tuesday, July 25 th at 10 a.m. EDT.... Read More

In Conjunction with Offering, Interim TORREY OLE Data and PROSERA Phase 3 Design Disclosed via 8-K; Conference Call to Discuss Data and Phase 3 Design with Leading PAH KOLs to be Held on July 25 th SAN DIEGO / Jul 20, 2023 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial... Read More

SAN DIEGO / May 18, 2023 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced data from its Phase 2 TORREY Study of seralutinib in patients with PAH will be featured in two sessions at the American Thoracic Society 2023 International Conference... Read More

Feedback on Planned Registrational Program for Seralutinib Received from FDA and EMA following Successful Phase 2 TORREY Study Registrational Phase 3 Clinical Trial in PAH Patients Expected to Initiate in 3Q23 Initial TORREY Study Open-Label Extension Data Expected Mid 2023 Operational Restructuring Implemented to Prioritize Seralutinib $202 million in cash, cash equivalents & marketable securities, as of March 31, 2023 SAN... Read More

SAN DIEGO / Mar 17, 2023 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2022 and provided a business update. Clinical-Stage Product Candidate... Read More

Primary Endpoint, Change in PVR at Week 24, Met with P-Value of 0.0310 Secondary Endpoint, Change in 6MWD, Numerically Favored Seralutinib Statistically Significant Improvements Observed in NT-proBNP and ECHO Measures of Cardiac Structure and Function Consistently Positive Results Seen Across Pre-Specified Sub-Groups, Including Statistically Significant Placebo-Adjusted Improvements of 21% in PVR and 37 Meters in 6MWD in WHO... Read More